Zacks Research Upgrades Chemours (NYSE:CC) to Hold

Key Points

• Zacks Research upgraded Chemours to “Hold” from “Strong Sell.” The stock has an average analyst rating of “Hold,” with a consensus price target of $20.10 versus its recent price of $15.04.
• Chemours reported quarterly EPS of $0.42, below the $0.49 consensus estimate, while revenue of $1.59 billion also missed expectations and declined 1.5% year over year.
• Insiders purchased shares worth about $130,601 over the past three months, while institutional investors and hedge funds own 76.26% of the company.

Chemours (NYSE:CC - Get Free Report) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating in a research report issued on Thursday, Zacks reports.

A number of other research analysts have also recently issued reports on the stock. Weiss Ratings cut shares of Chemours from a "sell (d)" rating to a "sell (d-)" rating in a report on Thursday, August 6th. Alembic Global Advisors reissued an "overweight" rating and set a $30.00 price target on shares of Chemours in a research note on Wednesday, May 13th. Royal Bank Of Canada lowered their price target on Chemours from $26.00 to $22.00 and set an "outperform" rating on the stock in a report on Thursday, August 6th. UBS Group reaffirmed a "neutral" rating and issued a $18.00 price objective (down from $29.00) on shares of Chemours in a research note on Monday, August 10th. Finally, The Goldman Sachs Group reaffirmed a "neutral" rating and set a $17.00 price objective on shares of Chemours in a report on Thursday, August 13th. Five analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Chemours presently has an average rating of "Hold" and an average price target of $20.10.

Chemours Stock Down 0.2%

Chemours stock opened at $15.04 on Thursday. The stock's 50 day moving average price is $16.39 and its 200 day moving average price is $19.64. Chemours has a 1-year low of $10.44 and a 1-year high of $28.67. The company has a market cap of $2.26 billion, a PE ratio of -7.88 and a beta of 1.42. The company has a debt-to-equity ratio of 18.98, a current ratio of 1.66 and a quick ratio of 0.88.

Chemours (NYSE:CC - Get Free Report) last issued its earnings results on Tuesday, August 4th. The specialty chemicals company reported $0.42 EPS for the quarter, missing the consensus estimate of $0.49 by ($0.07). Chemours had a positive return on equity of 60.64% and a negative net margin of 5.00%.The company had revenue of $1.59 billion for the quarter, compared to analysts' expectations of $1.65 billion. During the same quarter in the previous year, the firm posted ($2.54) earnings per share. Chemours's revenue for the quarter was down 1.5% on a year-over-year basis. On average, sell-side analysts predict that Chemours will post 0.87 EPS for the current fiscal year.

Insider Transactions at Chemours

In related news, insider Calderon Gerardo Familiar acquired 1,935 shares of the firm's stock in a transaction that occurred on Wednesday, August 12th. The shares were acquired at an average price of $15.53 per share, with a total value of $30,050.55. Following the completion of the purchase, the insider directly owned 58,547 shares in the company, valued at approximately $909,234.91. The trade was a 3.42% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Denise Dignam acquired 3,378 shares of the company's stock in a transaction that occurred on Tuesday, August 11th. The shares were bought at an average price of $14.95 per share, with a total value of $50,501.10. Following the transaction, the chief executive officer owned 339,916 shares in the company, valued at $5,081,744.20. This represents a 1.00% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders purchased a total of 8,663 shares of company stock valued at $130,601 over the last three months. 0.85% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Chemours

Several hedge funds have recently modified their holdings of the company. Annis Gardner Whiting Capital Advisors LLC purchased a new stake in shares of Chemours in the first quarter valued at $3,745,000. Old West Investment Management LLC acquired a new position in Chemours in the second quarter valued at $7,152,000. BlackRock Inc. purchased a new position in Chemours during the second quarter worth about $477,769,000. Deutsche Bank AG purchased a new position in Chemours during the second quarter worth about $3,291,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in Chemours in the 2nd quarter worth about $1,467,000. 76.26% of the stock is owned by institutional investors and hedge funds.

More Chemours News

Here are the key news stories impacting Chemours this week:

• Positive Sentiment: Chemours, DuPont and Corteva agreed to pay $455 million over 15 years to resolve claims brought by North Carolina and 11 local entities involving PFAS and other historical discharges from Chemours’ Fayetteville Works plant, as well as certain AFFF-related claims. Chemours’ share is approximately $180 million on a net-present-value basis, and the company said the obligation is covered by existing accruals, limiting the immediate earnings impact. Chemours, DuPont and Corteva Reach Agreement to Resolve PFAS-Related Claims in North Carolina
• Positive Sentiment: The settlement removes a significant portion of litigation uncertainty tied to the Fayetteville Works site and clarifies future cash obligations, which investors viewed favorably. Reports indicated Chemours shares rose during the session following the announcement. Why Is Chemours Stock Trading Higher Today?
• Neutral Sentiment: Several reports describe the agreement as a $380 million settlement with 11 public entities, while other headlines cite $590 million. These figures appear to reflect different components or descriptions of the broader resolution; the companies’ announced terms identify total settlement payments of $455 million over 15 years. Chemours, DuPont, Corteva settle North Carolina forever chemicals claims for $455 million
• Negative Sentiment: The agreement still represents a substantial long-term liability and does not eliminate broader PFAS-related regulatory, cleanup or litigation risks. Chemours’ results already show pressure from weaker revenue and an earnings miss, making continued legal-cost management important for investors.

Chemours Company Profile

The Chemours Company NYSE: CC is a global chemistry company headquartered in Wilmington, Delaware. Formed in 2015 through a spin-off from DuPont, Chemours develops and manufactures chemical products used in industries including transportation, electronics, energy, construction, and consumer goods.

The company operates through businesses focused on thermal and specialized solutions, titanium technologies, and advanced performance materials. Its products include refrigerants and heat-transfer fluids, titanium dioxide pigments used to provide whiteness and opacity in coatings, plastics, and paper, as well as fluoropolymers, specialty fluids, and other performance materials used in demanding industrial applications.

Chemours serves customers in North America, Latin America, Europe, the Asia-Pacific region, and other international markets through manufacturing facilities, research and development operations, and commercial activities around the world.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.